The National Institute on Drug Abuse (NIDA) offers funding for small business concerns (SBCs) to advance the development of pharmacological treatment agents for drug and nicotine abuse. This grant is specifically for renewing previously funded Phase II SBIR projects to progress existing compounds to the next stage of drug discovery and development.
Opportunity ID: 44931
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PA-06-036 |
| Funding Opportunity Title: | NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jan 26, 2009 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – Multiple Receipt Dates – See Link to Full Announcement for details. |
| Current Closing Date for Applications: | – Multiple Receipt Dates – See Link to Full Announcement for details. |
| Archive Date: | Oct 02, 2009 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $750,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) Small businesses |
| Additional Information on Eligibility: | Foreign institutions are not eligible to apply. Only United States small business concerns (SBCs) are eligible to submit SBIR applications. A small business concern is one that, at the time of award for both Phase I and Phase II SBIR awards, meets all of the following criteria: 1. Is independently owned and operated, is not dominant in the field of operation in which it is proposing, has a place of business in the United States and operates primarily within the United States or makes a significant contribution to the U.S. economy, and is organized for profit. 2. Is at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States, or (b) for SBIR only, it must be a for-profit business concern that is at least 51% owned and controlled by another for-profit business concern that is at least 51% owned and controlled by one or more individuals who are citizens of, or permanent re! sident aliens, in the United States. 3. Has, including its affiliates, an average number of employees for the preceding 12 months not exceeding 500, and meets the other regulatory requirements found in Title 13 Code of Federal Regulations (CFR) Part 121. Business concerns are generally considered to be affiliates of one another when either directly or indirectly, (a) one concern controls or has the power to control the other; or (b) a third-party/parties controls or has the power to control both. Control can be exercised through common ownership, common management, and contractual relationships. The term "affiliates" is defined in greater detail in 13 CFR 121.103. The term "number of employees" is defined in 13 CFR 121.106 — Small Business Size Regulations. A business concern may be in the form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust, or cooperative. Further information may be obtaine! d at http://sba.gov/size, or by contacting the Small Business Administ ration’s (SBA) Government Contracting Area Office or Office of Size Standards. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose the advanced stage development of pharmacological treatment agents for drug and nicotine abuse and dependence. This FOA specifically invites applications for the competing renewal (formerly competing continuation ) of previously funded Phase II SBIR grants, to take existing, promising compounds through the next step of drug discovery and development. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PA-06-036.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.279 | ADOBE-FORMS-A | Adobe-Forms-A | PKG00010141 | Jan 26, 2009 | Sep 07, 2009 | View |
Package 1
Mandatory forms
44931 RR_SF424-1.1.pdf
44931 RR_OtherProjectInfo-1.1.pdf
44931 RR_PerformanceSite-1.1.pdf
44931 RR_Budget-1.1.pdf
44931 SBIR_STTR_Information-1.0.pdf
44931 PHS398_CoverPageSupplement-1.1.pdf
44931 PHS398_ResearchPlan-1.1.pdf
44931 PHS398_Checklist-1.1.pdf
Optional forms
44931 PHS398_CoverLetter-1.1.pdf
44931 RR_SubawardBudget-1.2.pdf
Leave a Reply